Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dhanvantri Jeevan RekhaBOM:531043 +3.90%70 Return-on-Tangible-Asset is 4.10% as of Jun. 2026, which is 127% above its 10-year median of 1.81. GuruFocus rates BOM:531043 with a GF Score™ of 70/100 and a GF Value™ of ₹28.11 (Fairly Valued). The stock has 2 warning signs investors should review. Among 681 Healthcare Providers & Services companies, Dhanvantri Jeevan Rekha ranks better than 52.13% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Dhanvantri Jeevan Rekha's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹7.2 Mil. Dhanvantri Jeevan Rekha's average total tangible assets for the quarter that ended in Jun. 2026 was ₹175.7 Mil. Therefore, Dhanvantri Jeevan Rekha's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 4.10%.
The historical rank and industry rank for Dhanvantri Jeevan Rekha's Return-on-Tangible-Asset or its related term are showing as below:
BOM:531043'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -9.92 Med: 1.81 Max: 4.46
Current: 3.18
During the past 13 years, Dhanvantri Jeevan Rekha's highest Return-on-Tangible-Asset was 4.46%. The lowest was -9.92%. And the median was 1.81%.
BOM:531043's Return-on-Tangible-Asset is ranked better than 52.13% of 681
companies
in the Healthcare Providers & Services industry
Industry Median: 2.64
vs BOM:531043: 3.18
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Dhanvantri Jeevan Rekha Return-on-Tangible-Asset Related Terms
Dhanvantri Jeevan Rekha Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Dhanvantri Jeevan Rekha's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:531043 vs HCA, THC, EHC: Return-on-Tangible-Asset Comparison
For the Medical Care Facilities subindustry, Dhanvantri Jeevan Rekha's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dhanvantri Jeevan Rekha Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dhanvantri Jeevan Rekha's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Dhanvantri Jeevan Rekha's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 4.10% mean?
Dhanvantri Jeevan Rekha (BOM:531043) has a Return-on-Tangible-Asset of 4.10% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Dhanvantri Jeevan Rekha and its competitors. This is 127% above median its historical median of 1.81. According to the industry distribution chart, Dhanvantri Jeevan Rekha ranks #326 out of 681 companies in the Healthcare Providers & Services industry, placing it in the top 47.9%.
Is Dhanvantri Jeevan Rekha's Return-on-Tangible-Asset too high?
Dhanvantri Jeevan Rekha's current Return-on-Tangible-Asset of 4.10% is 127% above median its 10-year median of 1.81. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.64. Dhanvantri Jeevan Rekha's value of 4.10% is 55.3% above this industry median. Based on the distribution chart, Dhanvantri Jeevan Rekha ranks #326 out of 681 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Dhanvantri Jeevan Rekha has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dhanvantri Jeevan Rekha's Return-on-Tangible-Asset compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Dhanvantri Jeevan Rekha ranks #326 out of 681 companies for Return-on-Tangible-Asset. This puts Dhanvantri Jeevan Rekha in the upper half of its industry. The industry median Return-on-Tangible-Asset is 2.64. Dhanvantri Jeevan Rekha's value of 4.10% is 55.3% above this benchmark. While the company's 10-year median is 1.81 vs. the industry median of 2.64, Dhanvantri Jeevan Rekha has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.64, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dhanvantri Jeevan Rekha's current Return-on-Tangible-Asset of 4.10% is 55.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Dhanvantri Jeevan Rekha and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dhanvantri Jeevan Rekha's current Return-on-Tangible-Asset is 4.10%, which is 127% above median its own 10-year median of 1.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dhanvantri Jeevan Rekha stock overvalued right now?
Based on GuruFocus' analysis, Dhanvantri Jeevan Rekha (BOM:531043) is currently considered Fairly Valued. The stock's GF Value™ is ₹28.11, compared to a current price of ₹27.69 — trading 1.5% below its estimated fair value. The current Return-on-Tangible-Asset is 4.10%, which is 127% above median its 10-year median of 1.81 and 55.3% above the Healthcare Providers & Services industry median of 2.64. Dhanvantri Jeevan Rekha's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Dhanvantri Jeevan Rekha (BOM:531043), the current Return-on-Tangible-Asset is 4.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dhanvantri Jeevan Rekha (BOM:531043) Overvalued in 2026?
Based on GuruFocus' analysis, Dhanvantri Jeevan Rekha stock appears to be undervalued.
The current stock price of ₹27.69 is trading 1.5% below its estimated GF Value™ of ₹28.11.
GuruFocus considers Dhanvantri Jeevan Rekha to be Fairly Valued.
Key valuation signals for BOM:531043:
Return-on-Tangible-Asset: 4.10% (127% above median its 10-year median of 1.81)
GF Value™: ₹28.11 vs. price of ₹27.69 (1.5% below fair value)
Industry Position: 55.3% above the Healthcare Providers & Services median (#326 of 681)
No single metric tells the full story. See the BOM:531043 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dhanvantri Jeevan Rekha Ltd is engaged in providing diagnostic and therapeutic services and has extended its scope of diagnostic and hospital services by providing a fully operational Cath Lab, catering to higher end needs of the cardiac patients including Angiography, Angioplasty, Pacemaker Implantation, Valvuloplasty etc. The hospital has expanded its services to include a wide range of specialties such as Cardiology, Neurology, Orthopedics, Radiology, Gastroenterology, General Surgery, Urology, and General Medicine.
70GF Score
Get the complete analysis for BOM:531043
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531043 has been successfully added to your 
